The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic

Vaccine

Volumn 29, Issue 9, 2011, Pages 1777-1782

  Engelhard, Dan ^a   Zakay Rones, Zichria ^b   Shapira, Michael Y ^a   Resnick, Igor ^a   Averbuch, Diana ^a   Grisariu, Sigal ^a   Dray, Lillian ^a   Djian, Esther ^a   Strauss Liviatan, Nurith ^a   Grotto, Itamar ^c,d   Wolf, Dana G ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MINISTRY OF HEALTH   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

2009 A(H1N1) influenza pandemic; A California 7 2009 vaccine; Hematopoietic stem cell transplantation; Humoral immune response; Vaccination

Indexed keywords

AS 03; CYCLOSPORIN; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; STEROID; THIOMERSAL; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DONOR; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; INFLUENZA VACCINATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; STEROID THERAPY;

EID: 79952703352     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.113     Document Type: Article

References (29)

1. Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993;17(August (2)):244-7.
2. Whimbey E, Elting LS, Couch RB, Lo W,Williams L, Champlin RE, et al. Influenza A virus infections among hospitalized dult bone arrow transplant recipients. Bone Marrow Transplant 1994;13(April (4)):437-40.
3. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001;7(Suppl):5S-7S.
4. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39(November (9)):1300-6.
5. Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 2001;28(October (8)):775-81.
6. Pauksen K, Linde A, Hammarstrom V, Sjolin J, Carneskog J, Jonsson G, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000;30(February (2)):342-8.
7. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86(July (2)):257-63.
8. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11(January (1)):1-5.
9. Kunisaki KM, Janoff EN. Influenza inimmuno suppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9(August (8)):493-504.
10. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al.Vac-cination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009;44(October (8)):521-6.
11. Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection -United States, April-August 2009. MMWR 2009;58(September (34)):941-7.
12. Sever J. Application of microtechnique to viral serological investigation. J Immunol 1962;88:321-5.
13. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010;51(September (6)):668-77.
14. Engelhard D, Bromberg M, Averbuch A, Tenenbaum A, Goldmann D, Kunin M, et al. Increased burden and risk factors of pediatric 2009 A(H1N1) pandemic versus seasonal influenza in Israel. Submitted for publication.
15. CDC. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009;58(19):521-4.
16. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361(November (20)):1945-52.
17. EMA. Note for guidance on harmonization of requirements for influenza vaccines; 1997. Available from: www.ema.europa.eu/pdfs/human/bwp/021496en.pdf.
18. Parkman R, Weinberg KI. Immunological reconstitution following hematopoietic stem cell transplantation. In: Blume KG, Forman SI. Appelbaum F, editor. Thomas'shematopoietic celltransplantation. Malden:Blackwell Science; 2003. p. 853-61.
19. Storek J, Witherspon RP. Immunological reconstitution after hemopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, BrennerMK, editors. Clinical bone marrow and blood stem cell transplantation. Cambridge: Cambridge University Press; 2004.
20. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 2001;28(September (5)):479-84.
21. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Ahmed A, Nieto, et al. H1N1 infections in haematopoietic stem-cell transplant recipients: a prospective survey by the infectious diseases working party of the European group for blood and marrow transplantation and the infectious complications subcommittee of the GETH (Spanish group of haematopoietic stem-cell transplantation). Submitted for publication.
22. Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J, et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningo-coccus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007;44(March (5)):625-34.
23. Nordoy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccina-tions accordingtoEBMT guidelines. Bone Marrow Transplant 2001;28(October (7)):681-7.
24. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, et al. Immuno-logic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31(October (10)):941-52.
25. Sanchez-Guijo FM, Sanchez-Abarca LI, Bueno C, Villaron E, Lopez-Holgado N, VazquezL,etal. Long-term immune recoveryofpatients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors. Biol Blood Marrow Transplant 2005;11(May (5)):354-61.
26. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, et al. Seroprotec-tive titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant, 2010 October 13.
27. Baron F, Storer B, Maris MB, Storek J, Piette F, Metcalf M, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006;12(November (11)):1176-87.
28. Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, et al. Risk factors for fatal infectious complications developing late after allo-geneic stem cell transplantation. Bone Marrow Transplant 2007;40(December (11)):1055-62.
29. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115(May (19)):3861-8.